Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer.
Authors
Sarabjot Pabla
OmniSeq, Inc., Buffalo, NY
Sarabjot Pabla, Erik Van Roey, Jeffrey M. Conroy, Sean Glenn, Yirong Wang, Mary Nesline, Blake Burgher, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Carl Morrison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 47)
Abstract #
47
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.
First Author: Yanyan Lou
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Annual Meeting
Large-scale transcriptomic profiling of the tumor immune microenvironment in ALK+ lung cancer.
First Author: Vincent K. Lam
Poster
2022 ASCO Annual Meeting
Comprehensive genomic and immune profiling defines immunotherapy treatment in patients with NSCLC with low PD-L1 IHC.
First Author: Sarabjot Pabla